GSA Capital Partners LLP Sells 52,213 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

GSA Capital Partners LLP trimmed its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 84.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,417 shares of the biotechnology company’s stock after selling 52,213 shares during the period. GSA Capital Partners LLP’s holdings in Arcturus Therapeutics were worth $219,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Russell Investments Group Ltd. acquired a new position in shares of Arcturus Therapeutics during the 1st quarter valued at $40,000. ProShare Advisors LLC acquired a new position in shares of Arcturus Therapeutics during the first quarter valued at about $205,000. State Board of Administration of Florida Retirement System boosted its position in shares of Arcturus Therapeutics by 32.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,841 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 2,160 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 428 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Arcturus Therapeutics by 5.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 922 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 15.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have issued reports on ARCT shares. Leerink Partners assumed coverage on Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research note on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Buy” and an average price target of $71.40.

Arcturus Therapeutics Price Performance

ARCT opened at $16.91 on Monday. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $14.93 and a fifty-two week high of $45.00. The firm has a market capitalization of $458.09 million, a P/E ratio of -7.62 and a beta of 2.64. The company’s 50-day moving average is $20.22 and its 200 day moving average is $23.60.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. During the same quarter in the prior year, the company earned ($0.61) EPS. On average, equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.31 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.